DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY

Information source: Groupe Hospitalier Pitie-Salpetriere
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV

Intervention: stavudine (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Groupe Hospitalier Pitie-Salpetriere

Official(s) and/or principal investigator(s):
Manuela BONMARCHAND, MD, Study Chair, Affiliation: Service de médecine Interne Hôpital Pitié Salpêtrière
Hocine AIT-MOHAND, MD, Study Chair, Affiliation: Service de Maladies Infectieuses Hôpital Pitié Salpêtrière

Summary

Lipodystrophie, peripheral neuropathy and mitochondrial toxicity has been associated to stavudine at standard doses The aim of this study is to evaluate the efficacy of reduced doses of stavudine (30 mg b. i.d.) in HIV patients with controlled viral load and body weight > 60 kg, receiving an antiretroviral therapy containing stavudine 40 mg b. i.d.

Clinical Details

Official title: Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Proportion of patients with viral load < 400 copies/ml at week S24

Secondary outcome: Clinical and biological safety of the reduced doses of stavudine at week 24. Percentage of patients with viral load < 400 copies/ml at week 48, evolution of Cd4 count from baseline to W24 and 48. Evolution of metabolic parameters from baseline to W24 and

Detailed description: Stavudine is a nucleoside inhibitor larged used in HIV treatments and has been associated to mithocondrial toxicity. As it is still largely used in developping countries,the evaluation of reducing dose is of importance. A single-arm open pilot 48 weeks study to evaluate the capacity of a switch from d4T 40 mg to 30 mg bid in patients with body weight > 60kg to maintain full viral load suppression. Clinical and biological evaluations were carried out at baseline, W24 and W48. Primary end-point is viral load suppression (<400 coies/ml) at W24. Secondary end-points are : Evolution of CD4 count at W24 and W48, neurological examination at Baseline, W24 and W48, metabolic parameters and stavudine PK at W24.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- HIV patients

- Patients with an antiretroviral treatment containing stavudine at standard doses

(40mg BID) for at least 3 months

- Patients with viral load < 400 copies/ml for at least 3 months

Exclusion Criteria:

- Patients receiving an antiretroviral therapy containing stavudine at 30mg BID

- Current Opportunistic Infection

- Current chemotherapy or under cytokines treatment (PEG, INF, IL2)

- Pregnant or feeding Women

Locations and Contacts

Service de Maladies Infectieuses Hôpital Pitié-Salpêtrière, Paris 75013, France
Additional Information

Starting date: June 2004
Last updated: October 24, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017